Substance P microinjected into the periaqueductal gray matter induces antinociception and is released following morphine administration.
D000700:Analgesics / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003956:Dialysis / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008297:Male; D008845:Microinjections / Q000379:methods; D009020:Morphine / Q000008:administration & dosage / Q000627:therapeutic use; D009294:Narcotics / Q000008:administration & dosage / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement / Q000187:drug effects; D010487:Periaqueductal Gray / Q000187:drug effects*; D011188:Potassium / Q000494:pharmacology; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D013373:Substance P / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D000700:Analgesics; D009294:Narcotics; D013373:Substance P; D009020:Morphine; C042867:spantide; D011188:Potassium